Literature DB >> 31718297

Baseline Predictors of Low-Density Lipoprotein Cholesterol and Systolic Blood Pressure Goal Attainment After 1 Year in the ISCHEMIA Trial.

Jonathan D Newman1, Karen P Alexander2, Xiangqiong Gu2, Sean M O'Brien2, William E Boden3, Sajeev C Govindan4, Roxy Senior5, Nagaraja Moorthy6, Paulo C Rezende7, Marcin Demkow8, Jose Luis Lopez-Sendon9, Olga Bockeria10, Neeraj Pandit11, Gilbert Gosselin12, Peter H Stone13, John A Spertus14, Gregg W Stone15, Jerome L Fleg16, Judith S Hochman1, David J Maron17.   

Abstract

BACKGROUND: Risk factor control is the cornerstone of managing stable ischemic heart disease but is often not achieved. Predictors of risk factor control in a randomized clinical trial have not been described. METHODS AND
RESULTS: The ISCHEMIA trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches) randomized individuals with at least moderate inducible ischemia and obstructive coronary artery disease to an initial invasive or conservative strategy in addition to optimal medical therapy. The primary aim of this analysis was to determine predictors of meeting trial goals for LDL-C (low-density lipoprotein cholesterol, goal <70 mg/dL) or systolic blood pressure (SBP, goal <140 mm Hg) at 1 year post-randomization. We included all randomized participants in the ISCHEMIA trial with baseline and 1-year LDL-C and SBP values by January 28, 2019. Among the 3984 ISCHEMIA participants (78% of 5179 randomized) with available data, 35% were at goal for LDL-C, and 65% were at goal for SBP at baseline. At 1 year, the percent at goal increased to 52% for LDL-C and 75% for SBP. Adjusted odds of 1-year LDL-C goal attainment were greater with older age (odds ratio [OR], 1.11 [95% CI, 1.03-1.20] per 10 years), lower baseline LDL-C (OR, 1.19 [95% CI, 1.17-1.22] per 10 mg/dL), high-intensity statin use (OR, 1.30 [95% CI, 1.12-1.51]), nonwhite race (OR, 1.32 [95% CI, 1.07-1.63]), and North American enrollment compared with other regions (OR, 1.32 [95% CI, 1.06-1.66]). Women were less likely than men to achieve 1-year LDL-C goal (OR, 0.68 [95% CI, 0.58-0.80]). Adjusted odds of 1-year SBP goal attainment were greater with lower baseline SBP (OR, 1.27 [95% CI, 1.22-1.33] per 10 mm Hg) and with North American enrollment (OR, 1.35 [95% CI, 1.04-1.76]).
CONCLUSIONS: In ISCHEMIA, older age, male sex, high-intensity statin use, lower baseline LDL-C, and North American location predicted 1-year LDL-C goal attainment, whereas lower baseline SBP and North American location predicted 1-year SBP goal attainment. Future studies should examine the effects of sex disparities, international practice patterns, and provider behavior on risk factor control.

Entities:  

Keywords:  blood pressure; cardiovascular disease; goals; heart disease; risk factor

Mesh:

Substances:

Year:  2019        PMID: 31718297      PMCID: PMC7157834          DOI: 10.1161/CIRCOUTCOMES.119.006002

Source DB:  PubMed          Journal:  Circ Cardiovasc Qual Outcomes        ISSN: 1941-7713


  28 in total

1.  Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry.

Authors:  Kornelia Kotseva; Guy De Backer; Dirk De Bacquer; Lars Rydén; Arno Hoes; Diederick Grobbee; Aldo Maggioni; Pedro Marques-Vidal; Catriona Jennings; Ana Abreu; Carlos Aguiar; Jolita Badariene; Jan Bruthans; Almudena Castro Conde; Renata Cifkova; Jim Crowley; Kairat Davletov; Jaap Deckers; Delphine De Smedt; Johan De Sutter; Mirza Dilic; Marina Dolzhenko; Vilnis Dzerve; Andrejs Erglis; Zlatko Fras; Dan Gaita; Nina Gotcheva; Peter Heuschmann; Hosam Hasan-Ali; Piotr Jankowski; Nebojsa Lalic; Seppo Lehto; Dragan Lovic; Silvia Mancas; Linda Mellbin; Davor Milicic; Erkin Mirrakhimov; Rafael Oganov; Nana Pogosova; Zeljko Reiner; Stefan Stöerk; Lâle Tokgözoğlu; Costas Tsioufis; Dusko Vulic; David Wood
Journal:  Eur J Prev Cardiol       Date:  2019-02-10       Impact factor: 7.804

2.  Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.

Authors:  Marc A Pfeffer; Brian Claggett; Susan F Assmann; Robin Boineau; Inder S Anand; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; John F Heitner; Eldrin F Lewis; Eileen O'Meara; Jean-Lucien Rouleau; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Sonja M McKinlay; Bertram Pitt
Journal:  Circulation       Date:  2014-11-18       Impact factor: 29.690

Review 3.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  J Am Coll Cardiol       Date:  2017-11-13       Impact factor: 24.094

4.  Development and validation of a short version of the Seattle angina questionnaire.

Authors:  Paul S Chan; Philip G Jones; Suzanne A Arnold; John A Spertus
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-09-02

5.  Influence of global region on outcomes in heart failure β-blocker trials.

Authors:  Christopher M O'Connor; Mona Fiuzat; Karl Swedberg; Michael Caron; Bruce Koch; Peter E Carson; Wendy Gattis-Stough; Gordon W Davis; Michael R Bristow
Journal:  J Am Coll Cardiol       Date:  2011-08-23       Impact factor: 24.094

6.  Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry.

Authors:  Chiara Melloni; Bimal R Shah; Fang-Shu Ou; Matthew T Roe; Sidney C Smith; Charles V Pollack; Magnus Ohman; W Brian Gibler; Eric D Peterson; Karen P Alexander
Journal:  Am Heart J       Date:  2010-12       Impact factor: 4.749

Review 7.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

8.  Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial.

Authors:  David J Maron; G B John Mancini; Pamela M Hartigan; John A Spertus; Steven P Sedlis; William J Kostuk; Daniel S Berman; Koon K Teo; William S Weintraub; William E Boden
Journal:  J Am Coll Cardiol       Date:  2018-11-06       Impact factor: 24.094

9.  Sex, Prescribing Practices and Guideline Recommended, Blood Pressure, and LDL Cholesterol Targets at Baseline in the BARI 2D Trial.

Authors:  Michelle F Magee; Jacqueline E Tamis-Holland; Jiang Lu; Vera A Bittner; Maria Mori Brooks; Neuza Lopes; Alice K Jacobs
Journal:  Int J Endocrinol       Date:  2015-03-19       Impact factor: 3.257

10.  Explaining the decrease in U.S. deaths from coronary disease, 1980-2000.

Authors:  Earl S Ford; Umed A Ajani; Janet B Croft; Julia A Critchley; Darwin R Labarthe; Thomas E Kottke; Wayne H Giles; Simon Capewell
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

View more
  5 in total

1.  Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial.

Authors:  Mandeep S Sidhu; Karen P Alexander; Zhen Huang; Sean M O'Brien; Bernard R Chaitman; Gregg W Stone; Jonathan D Newman; William E Boden; Aldo P Maggioni; Philippe Gabriel Steg; Thomas B Ferguson; Marcin Demkow; Jesus Peteiro; Gurpreet S Wander; Denis C Phaneuf; Mark A De Belder; Rolf Doerr; Erick Alexanderson-Rosas; Carisi A Polanczyk; Peter A Henriksen; Dwayne S G Conway; Vicente Miro; Tali Sharir; Renato D Lopes; James K Min; Daniel S Berman; Frank W Rockhold; Stephen Balter; David Borrego; Yves D Rosenberg; Sripal Bangalore; Harmony R Reynolds; Judith S Hochman; David J Maron
Journal:  Am Heart J       Date:  2022-02-09       Impact factor: 5.099

2.  Outcomes of Participants With Diabetes in the ISCHEMIA Trials.

Authors:  Jonathan D Newman; Rebecca Anthopolos; G B John Mancini; Sripal Bangalore; Harmony R Reynolds; Dennis F Kunichoff; Roxy Senior; Jesus Peteiro; Balram Bhargava; Pallav Garg; Jorge Escobedo; Rolf Doerr; Tomasz Mazurek; Jose Gonzalez-Juanatey; Grzegorz Gajos; Carlo Briguori; Hong Cheng; Andras Vertes; Sandeep Mahajan; Luis A Guzman; Matyas Keltai; Aldo P Maggioni; Gregg W Stone; Jeffrey S Berger; Yves D Rosenberg; William E Boden; Bernard R Chaitman; Jerome L Fleg; Judith S Hochman; David J Maron
Journal:  Circulation       Date:  2021-09-15       Impact factor: 29.690

3.  Achieving Optimal Medical Therapy: Insights From the ORBITA Trial.

Authors:  Michael Foley; Christopher A Rajkumar; Matthew Shun-Shin; Sashiananthan Ganesananthan; Henry Seligman; James Howard; Alexandra N Nowbar; Thomas R Keeble; John R Davies; Kare H Tang; Robert Gerber; Peter O'Kane; Andrew S P Sharp; Ricardo Petraco; Iqbal S Malik; Sukhjinder Nijjer; Sayan Sen; Darrel P Francis; Rasha Al-Lamee
Journal:  J Am Heart Assoc       Date:  2021-01-26       Impact factor: 5.501

4.  Use of guideline-recommended drug therapy in patients undergoing percutaneous coronary intervention for stable coronary heart disease in Germany: a multilevel analysis of nationwide routine data.

Authors:  Julia Frank-Tewaag; Julian Bleek; Dirk Horenkamp-Sonntag; Ursula Marschall; Uwe Zeymer; Norbert Donner-Banzhoff; Leonie Sundmacher
Journal:  BMJ Open       Date:  2020-12-13       Impact factor: 2.692

5.  Screening for participants in the ISCHEMIA trial: Implications for clinical research.

Authors:  Fatima Rodriguez; Judith S Hochman; Yifan Xu; Harmony R Reynolds; Jeffrey S Berger; Stavroula Mavromichalis; Jonathan D Newman; Sripal Bangalore; David J Maron
Journal:  J Clin Transl Sci       Date:  2022-07-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.